|
| Sources | Disease | Therapeutic schedule | Phase | Number | Evaluation | Outcome | Reference |
|
1 | Allogeneic- BMMSCs | UC | a single dose of (1.5-2) x 108 intravenously | II | 44 | 24 months | 34 (72.7%) of patients achieved the clinical and morphological indices of inflammatory activity↓. | [112] |
|
2 | Allogeneic- ADMSCs | Perianal fistulizing CD | a single dose of 1.2 x 108 intralesionally | III | 212 | 24 weeks | 50% of patients treated with ADMSCs achieved combined remission. | [113] |
|
3 | Allogeneic- ADMSCs | Perianal fistulizing CD | a single dose intralesionally If 2 x 107 failed, 4 x 107 subsequently | II | 24 | 24 weeks | 69.2% of patients achieved the number of draining fistulas↓ 56.3% of patients achieved complete fistula closure of the treated. 30% of patients achieved complete closure of all existing fistula tracts. | [114] |
|
4 | Allogeneic- BMMSCs | Perianal fistulizing CD | a single dose of 1 × 107, 3 × 107, or 9 × 107 intralesionally | II | 21 | 6, 12, and 24 weeks | no severe adverse events. 3 × 107 MSCs appeared to promote healing of perianal fistulas | [115] |
|
5 | Allogeneic-MSCs | Luminal CD | a single dose of 2 × 106 /kg weekly for 4 weeks intravenously | II | 16 | 42 days | 15 patients CDAI score ↓ from 370 to 203 at day 42 | [116] |
|
6 | Autologous-BMMSCs | Luminal CD | two doses of 1-2×106 intravenously, 7 days apart | I | 10 | 0, 6 weeks | 3 patients CDAI score ↓ at 6 weeks | [117] |
|
7 | Autologous-ADMSCs | Perianal fistulizing CD | local injection,2×107 | I | 12 | 24 weeks | 9 of 12 patients had complete clinical healing by 3 months, 10 of 12 patients (83.3%) had complete clinical healing at 6 months | [118] |
|
8 | Autologous-ADMSCs | Perianal fistulizing CD | group 1: 1 × 107 cells/ml. After 4 weeks, if safe, group 2: 2 × 107 cells/ml. After 4 weeks, if safe, group 3: 4 × 107 cells/ml | I | >9 | 8 weeks | 2 patients in group 2 showed complete healing and 3 patients in group 3 showed complete healing at week 8. | [119] |
|
9 | Autologous-BMMSCs | CD | a single dose of 2 × 107, 5 × 107, or 10 × 107 cells/kg intravenously | I | 12 | 2 weeks | Single infusion of BMMSCs propagated ex vivo using human platelet lysate-supplemented media was safe and feasible at the doses of up to 10 million cells/kg | [120] |
|
10 | Autologous-ADMSCs | Perianal fistulizing CD | 3 × 107 cells per centimeter length | II | 43 | 8 weeks | 27/33 patients (82%) had complete fistula healing. Of 27 patients, 23 patients (88%) sustained complete closure | [121] |
|